EditorialEditorial
How Should We Measure Peripheral Spondyloarthritis?
Laura C. Coates and William Tillett
The Journal of Rheumatology November 2021, jrheum.211043; DOI: https://doi.org/10.3899/jrheum.211043
Laura C. Coates
LCC is a National Institute for Health Research (NIHR) Clinician Scientist and Senior Clinical Research Fellow funded by an NIHR Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford; W. Tillett, MBChB, BSc, PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. WT has received research funding, consulting or speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, and UCB. LCC has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis and Pfizer; worked as a paid consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer, and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer, and UCB. Address correspondence to Prof. L.C. Coates, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK. Email: laura.coates@ndorms.ox.ac.uk.
William Tillett
LCC is a National Institute for Health Research (NIHR) Clinician Scientist and Senior Clinical Research Fellow funded by an NIHR Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford; W. Tillett, MBChB, BSc, PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. WT has received research funding, consulting or speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, and UCB. LCC has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis and Pfizer; worked as a paid consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer, and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer, and UCB. Address correspondence to Prof. L.C. Coates, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK. Email: laura.coates@ndorms.ox.ac.uk.
Abstract
Spondyloarthritis (SpA) is recognized as an overarching spectrum of disease characterized by axial SpA (axSpA), peripheral arthritis, enthesitis, and dactylitis. Despite significant overlap, patients are often characterized as having predominantly peripheral or axial involvement.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
How Should We Measure Peripheral Spondyloarthritis?
Laura C. Coates, William Tillett
The Journal of Rheumatology Nov 2021, jrheum.211043; DOI: 10.3899/jrheum.211043